ArticleWorld journal of microbiology & biotechnology2018
Modulation of S. aureus and P. aeruginosa biofilm: an in vitro study with new coumarin derivatives.
Article in World journal of microbiology & biotechnology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 18 citations in OpenAlex.
- Coumarins: Quorum Sensing and Biofilm Formation Inhibition.Molecules (Basel, Switzerland) · 2024Review
- Synthesis, biofilm formation inhibitory, and inflammation inhibitory activities of new coumarin derivatives.Scientific reports · 2024Article
- Pharmacological Characters and Toxicity Evaluation of Coumarin Derivative LP4C as Lead Compound against Biofilm Formation ofMolecules (Basel, Switzerland) · 2023Article
- Synthesis of new chrysin derivatives with substantial antibiofilm activity.Molecular diversity · 2022Article
- Pyrancoumarin derivative LP4C targeting of pyrimidineFrontiers in pharmacology · 2022Article
- In Vitro Effect of Copper (I) Complex [Cu(NNMicroorganisms · 2021Article
- Strategies for Interfering With Bacterial Early Stage Biofilms.Frontiers in microbiology · 2021Review
- Metabolomics Study Reveals Inhibition and Metabolic Dysregulation inFrontiers in microbiology · 2020Article
- Communication is the key: biofilms, quorum sensing, formation and prevention.Discoveries (Craiova, Romania) · 2019Review
- Advanced Drug-Eluting Poly (Vinyl Chloride) Surfaces Deposited by Spin Coating.Medicina (Kaunas, Lithuania) · 2019Article
Corrections and comments
- Erratum issued
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coumarin is an important heterocyclic molecular framework of bioactive molecules against broad spectrum pathological manifestations. In the present study 18 new coumarin derivatives (CDs) were synthesized and characterized for antibiofilm activity against two model bacteria such as Staphylococcus aureus and Pseudomonas aeruginosa. It was observed that all the CDs executed significant effect in moderating activities against both planktonic and biofilm forms of these selected bacteria. Hence, to interpret the underlying probable reason of such antibiofilm effect, in-silico binding study of CDs with biofilm and motility associated proteins of these organisms were performed. All CDs have shown their propensity for occupying the native substrate binding pocket of each protein with moderate to strong binding affinities. One of the CDs such as CAMN1 showed highest binding affinity with these proteins. Interestingly, the findings of in-silico studies coincides the experimental results of antibiofilm and motility affect of CDs against both S. aureus and P. aeruginosa. Moreover, in-silico studies suggested that the antibiofilm activity of test CDs may be due to the interference of biofilm and motility associated proteins of the selected model organisms (PilT from P. aeruginosa and TarK, TarO from S. aureus). The detailed synthesis, characterization, methodology and results of biological screening along with computational studies have been reported. This study could be of greater interest in the context of the development of new anti-bacterial agent in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.